A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06840003 In Patients With Malignant Gliomas

Trial Profile

A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06840003 In Patients With Malignant Gliomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs PF 6840003 (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 24 Jul 2017 Planned number of patients changed from 97 to 92.
    • 10 Mar 2017 Time frame of primary end point (Number of participants with disease control) has been changed from Baseline, Week 9 and Week 26 to Baseline, Week 9 and Week 25.
    • 10 Mar 2017 Planned number of patients changed from 92 to 97.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top